Skip to main content
CDC Website

Colleges/Universities

Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)

Human immunodeficiency virus (HIV) infection is widely prevalent in individuals in the reproductive age group. Globally, an estimated 1.3 million people living with HIV (PWH) become pregnant each year (UNAIDS data, 2019). With the advent of antiretroviral therapy (ART), significant progress has been made in the prevention of vertical transmission of HIV. However, although ART has clear benefits in preventing vertical transmission, ART regimens are associated with higher rates of preterm birth, stillbirth, and early infant death.

HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included.

Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)

This initiative will support multilevel and multidisciplinary intervention research to improve quality of life and promote successful aging among people with HIV with HIV associated non-AIDS comorbidities across the life course from racial and ethnic and lower socioeconomic status groups.

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional (R01 Clinical Trial Not Allowed)

The purpose of this initiative is to: 1.Support mining of SCORCH data to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/ART or SUD molecular responses 2.Support functional validation studies (e.g.

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional (R21 Clinical Trial Not Allowed)

The purpose of this initiative is to: 1.Support mining of SCORCH data to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/ART or SUD molecular responses 2.Support functional validation studies (e.g.

Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to identify cure strategies suitable for administration at the start of combination antiretroviral therapy (cART) and/or at cART restart after an analytical treatment interruption (ATI), with the ultimate goal of achieving sustained treatment-free remission.